Cargando…
First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia
BACKGROUND: The First Basal Insulin Evaluation (FINE) Asia study is a multinational, prospective, observational study of insulin-naïve Type 2 diabetes mellitus (T2DM) patients in Asia, uncontrolled (A1c ≥ 8%) on oral hypoglycemic agents, designed to evaluate the impact of basal insulin initiation. M...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178786/ https://www.ncbi.nlm.nih.gov/pubmed/21631903 http://dx.doi.org/10.1111/j.1753-0407.2011.00137.x |
_version_ | 1782212437125103616 |
---|---|
author | TSAI, Shih-Tzer PATHAN, Faruque JI, Linong YEUNG, Vincent Tok Fai CHADHA, Manoj SUASTIKA, Ketut SON, Hyun Shik TAN, Kevin Eng Kiat BENJASURATWONG, Yupin NGUYEN, Thy Khue IQBAL, Farrukh |
author_facet | TSAI, Shih-Tzer PATHAN, Faruque JI, Linong YEUNG, Vincent Tok Fai CHADHA, Manoj SUASTIKA, Ketut SON, Hyun Shik TAN, Kevin Eng Kiat BENJASURATWONG, Yupin NGUYEN, Thy Khue IQBAL, Farrukh |
author_sort | TSAI, Shih-Tzer |
collection | PubMed |
description | BACKGROUND: The First Basal Insulin Evaluation (FINE) Asia study is a multinational, prospective, observational study of insulin-naïve Type 2 diabetes mellitus (T2DM) patients in Asia, uncontrolled (A1c ≥ 8%) on oral hypoglycemic agents, designed to evaluate the impact of basal insulin initiation. METHODS: Basal insulin was initiated with or without concomitant oral therapy and doses were adjusted individually. All treatment choices, including the decision to initiate insulin, were at the physician's discretion to reflect real-life practice. RESULTS: Patients (n= 2679) from 11 Asian countries were enrolled (mean [±SD] duration of diabetes 9.3 ± 6.5 years; weight 68.1 ± 12.7 kg; A1c 9.8 ± 1.6%). After 6 months of basal insulin (NPH insulin, insulin glargine, or insulin detemir), A1c decreased to 7.7 ± 1.4%; 33.7% patients reached A1c <7%. Fasting blood glucose (FBG) decreased from 11.7 ± 3.6 to 7.2 ± 2.5 mmol/L and 36.8% of patients reached FBG <6.1 mmol/L. The mean daily insulin dose prescribed increased marginally from 0.18 to 0.23 U/kg per day at baseline to 0.22–0.24 U/kg per day at Month 6. Mean changes in body weight and reported rates of hypoglycemia were low over the duration of the study. CONCLUSIONS: Initiation of insulin therapy is still being delayed by approximately 9 years, resulting in many Asian patients developing severe hyperglycemia. Initiating insulin treatment with basal insulin was effective and safe in Asian T2DM patients in a real-world setting, but insulin needs may differ from those in Western countries. |
format | Online Article Text |
id | pubmed-3178786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-31787862011-09-28 First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia TSAI, Shih-Tzer PATHAN, Faruque JI, Linong YEUNG, Vincent Tok Fai CHADHA, Manoj SUASTIKA, Ketut SON, Hyun Shik TAN, Kevin Eng Kiat BENJASURATWONG, Yupin NGUYEN, Thy Khue IQBAL, Farrukh J Diabetes Asia Track BACKGROUND: The First Basal Insulin Evaluation (FINE) Asia study is a multinational, prospective, observational study of insulin-naïve Type 2 diabetes mellitus (T2DM) patients in Asia, uncontrolled (A1c ≥ 8%) on oral hypoglycemic agents, designed to evaluate the impact of basal insulin initiation. METHODS: Basal insulin was initiated with or without concomitant oral therapy and doses were adjusted individually. All treatment choices, including the decision to initiate insulin, were at the physician's discretion to reflect real-life practice. RESULTS: Patients (n= 2679) from 11 Asian countries were enrolled (mean [±SD] duration of diabetes 9.3 ± 6.5 years; weight 68.1 ± 12.7 kg; A1c 9.8 ± 1.6%). After 6 months of basal insulin (NPH insulin, insulin glargine, or insulin detemir), A1c decreased to 7.7 ± 1.4%; 33.7% patients reached A1c <7%. Fasting blood glucose (FBG) decreased from 11.7 ± 3.6 to 7.2 ± 2.5 mmol/L and 36.8% of patients reached FBG <6.1 mmol/L. The mean daily insulin dose prescribed increased marginally from 0.18 to 0.23 U/kg per day at baseline to 0.22–0.24 U/kg per day at Month 6. Mean changes in body weight and reported rates of hypoglycemia were low over the duration of the study. CONCLUSIONS: Initiation of insulin therapy is still being delayed by approximately 9 years, resulting in many Asian patients developing severe hyperglycemia. Initiating insulin treatment with basal insulin was effective and safe in Asian T2DM patients in a real-world setting, but insulin needs may differ from those in Western countries. Blackwell Publishing Ltd 2011-09 /pmc/articles/PMC3178786/ /pubmed/21631903 http://dx.doi.org/10.1111/j.1753-0407.2011.00137.x Text en Copyright © 2011 Ruijin Hospital and Blackwell Publishing Asia Pty Ltd http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Asia Track TSAI, Shih-Tzer PATHAN, Faruque JI, Linong YEUNG, Vincent Tok Fai CHADHA, Manoj SUASTIKA, Ketut SON, Hyun Shik TAN, Kevin Eng Kiat BENJASURATWONG, Yupin NGUYEN, Thy Khue IQBAL, Farrukh First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia |
title | First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia |
title_full | First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia |
title_fullStr | First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia |
title_full_unstemmed | First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia |
title_short | First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia |
title_sort | first insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in asia |
topic | Asia Track |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178786/ https://www.ncbi.nlm.nih.gov/pubmed/21631903 http://dx.doi.org/10.1111/j.1753-0407.2011.00137.x |
work_keys_str_mv | AT tsaishihtzer firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT pathanfaruque firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT jilinong firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT yeungvincenttokfai firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT chadhamanoj firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT suastikaketut firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT sonhyunshik firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT tankevinengkiat firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT benjasuratwongyupin firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT nguyenthykhue firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia AT iqbalfarrukh firstinsulinizationwithbasalinsulininpatientswithtype2diabetesinarealworldsettinginasia |